Financial Performance - The net profit attributable to the parent company's shareholders for 2024 is CNY 32,520,676.27[6]. - In 2024, the company's operating revenue increased by 3.51% year-on-year to CNY 318,349,489.92, while net profit attributable to shareholders decreased by 45.80% to CNY 32,520,676.27[24]. - The net profit excluding non-recurring gains and losses dropped by 62.07% year-on-year to CNY 17,145,709.78, reflecting significant challenges in the domestic market[26]. - Basic and diluted earnings per share fell by 45.45% to CNY 0.24, while the basic earnings per share after excluding non-recurring gains and losses decreased by 60.61% to CNY 0.13[25]. - The weighted average return on equity decreased by 2.76 percentage points to 3.06%, indicating a decline in profitability[25]. - The total assets at the end of 2024 reached CNY 1,466,011,224.89, an increase of 11.33% compared to the previous year[24]. - The net cash flow from operating activities improved significantly, reaching CNY 17,677,554.78, compared to a negative cash flow in 2023[24]. - The company reported a significant increase in revenue, achieving a total of $500 million for the quarter, representing a 25% year-over-year growth[149]. Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for 2024[6]. - The company will not distribute cash dividends or issue new shares for 2024, opting to retain profits for R&D and business expansion[175]. - The company’s cash dividend ratio for the year is 0.00%, reflecting a strategy focused on long-term growth and investment in R&D[175]. - The cumulative cash dividend amount over the last three accounting years was RMB 25,840,000.00, representing a cash dividend ratio of 37.23% of the average annual net profit[180]. - There were no cash dividends or stock bonuses declared for the current reporting period[179]. Operational Efficiency - The company has strengthened its operational capabilities through strict budget execution and lean production management, improving overall operational efficiency[37]. - The company reported a significant improvement in accounts receivable management, leading to better cash collection compared to previous years[26]. - The net cash flow from operating activities improved significantly, reaching 17.68 million yuan, attributed to better accounts receivable management[74]. - The company has implemented intelligent drug management projects in over 1,000 hospitals across 31 provinces, enhancing brand recognition[69]. Market Expansion and Strategy - The company is actively expanding into emerging businesses such as intelligent distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[26]. - The company plans to continue focusing on market expansion and new technology development to enhance future performance[26]. - The company established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros to promote its products in the Middle East and North Africa markets, aiming to enhance the digitalization and automation of the healthcare industry[34]. - The company is actively exploring the pharmaceutical retail market, planning to replicate the "smart pharmacy" model nationwide, integrating various product categories beyond pharmaceuticals[35]. - The company aims to expand its "to-G" business and overseas markets, particularly in the Middle East, Southeast Asia, and Europe, to increase its international influence and revenue share[123]. Research and Development - The company is increasing R&D investments to develop customized product solutions for overseas markets, enhancing its international brand influence and competitiveness[36]. - The R&D team has nearly 20 years of experience, enabling strong technical innovation and product development capabilities[65]. - The company plans to enhance its R&D capabilities and product development, focusing on market-oriented strategies and advanced technologies such as machine vision and deep learning[122]. - The company emphasizes the importance of R&D for maintaining competitive advantages in the pharmaceutical management sector[54]. Governance and Compliance - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[5]. - The company emphasizes the importance of the accuracy and completeness of the financial report[5]. - The internal control system was evaluated as effective with no significant deficiencies reported for financial reporting[183]. - The company has not reported any major differences in governance compared to regulations set by the China Securities Regulatory Commission[142]. Risks and Challenges - The company has described potential risks in the report, urging investors to pay attention[9]. - The overall economic environment remains challenging, impacting the company's performance and necessitating ongoing strategic adjustments[33]. - In 2024, the company faced challenges due to delayed payments and bad debt provisions, resulting in performance not meeting expectations[33]. Shareholder Commitments - The company commits to not transferring or entrusting the management of shares held before the issuance for 36 months post-listing[196]. - The actual controller, Dai Jianwei, and the actual controller, Sun Dong, have both committed to not transferring shares for 36 months post-IPO[193]. - The commitments include provisions for adjustments in case of changes to regulations regarding share transfers[193]. - The company has ensured that all relevant legal and regulatory requirements are being adhered to in relation to share transfers and commitments[195].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 318,036,293.50, representing a year-on-year increase of 17.92% compared to CNY 269,704,873.73 in the same period last year[4] - The net profit attributable to shareholders of the listed company improved to a loss of CNY 30,954,104.96, a 63.19% reduction from the loss of CNY 84,085,454.62 in the previous year[4] - The basic and diluted earnings per share were both CNY -0.06, showing a 64.71% improvement from CNY -0.17 in the same period last year[4] - The company reported a 64.02% reduction in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY -30,273,206.33 compared to CNY -84,149,353.28 last year[4] - Net profit for Q1 2025 was CNY -33,128,589.61, an improvement from CNY -89,854,438.14 in Q1 2024, representing a 63.1% reduction in losses[18] Cash Flow and Liquidity - The net cash flow from operating activities was CNY -85,053,601.94, a significant decline of 297.06% compared to CNY -21,421,102.69 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY -85,053,601.94, worsening from CNY -21,421,102.69 in the previous year[21] - Cash and cash equivalents at the end of Q1 2025 totaled CNY 64,238,345.97, down from CNY 147,573,604.98 at the end of Q1 2024[21] - The company's cash and cash equivalents decreased to CNY 205,772,077.16 from CNY 244,309,045.12, representing a decline of approximately 15.66%[14] - Investment activities resulted in a net cash outflow of CNY -253,404.23, compared to CNY -2,961,985.97 in Q1 2024[21] - Financing activities generated a net cash inflow of CNY 19,839,195.39, down from CNY 34,120,095.40 in the same period last year[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,620,902,493.92, down 6.98% from CNY 2,817,617,437.15 at the end of the previous year[5] - Current assets totaled CNY 1,970,697,408.01, down from CNY 2,155,963,222.29, indicating a decrease of about 8.58%[15] - Total liabilities were CNY 2,496,097,179.93, down from CNY 2,659,683,533.55, indicating a decrease of about 6.15%[16] - The total amount of contract liabilities decreased to CNY 352,140,772.67 from CNY 401,869,605.63, indicating a decline of approximately 12.25%[16] - The company's equity attributable to shareholders decreased by 22.24% to CNY 108,223,571.20 from CNY 139,177,676.16 at the end of the previous year[5] - The company's equity attributable to shareholders decreased to CNY 108,223,571.20 from CNY 139,177,676.16, a decline of approximately 22.24%[16] Research and Development - The company experienced a 58.20% decrease in R&D expenses, attributed to the initial phase of annual projects[8] - The company reported a significant increase in research and development expenses, totaling CNY 14,182,924.40 in Q1 2025, compared to CNY 33,931,553.52 in Q1 2024[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,499[10] Accounting Standards - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements from the beginning of that year[22]

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.22 billion, a decrease of 41.19% compared to ¥2.07 billion in 2023[26]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥401.45 million, representing a 240.31% increase in losses compared to a loss of ¥117.97 million in 2023[26]. - The basic earnings per share for 2024 was -¥0.82, a decline of 241.67% from -¥0.24 in 2023[27]. - The weighted average return on equity for 2024 was -118.02%, a decrease of 98.37 percentage points from -19.65% in 2023[27]. - The net cash flow from operating activities for 2024 was -¥159.91 million, a significant decline of 198.51% compared to -¥53.57 million in 2023[26]. - The total assets at the end of 2024 were approximately ¥2.82 billion, down 30.34% from ¥4.05 billion at the end of 2023[26]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥139.18 million, a decrease of 74.22% from ¥539.92 million at the end of 2023[26]. - The company reported a significant increase of 244.01% in net cash flow from financing activities, amounting to CNY 156,909,055.49, indicating improved financial management[132]. - The company's operating costs decreased by 38.99% to CNY 1,113,994,918.42, reflecting the impact of industry cycle fluctuations[132]. - The company reported a significant goodwill impairment of ¥103,856,394.34, up from ¥28,340,688.97 in the previous year due to industry cycle fluctuations[150]. Audit and Compliance - The company has received a standard unqualified audit report from Tianzhi International Accounting Firm[8]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management[8]. - The company faced a negative opinion from auditors regarding internal controls due to "abnormal prepayments" and was marked as "ST" in May 2024[43]. Research and Development - R&D investment accounted for 9.7% of total revenue, aimed at accelerating the development of new productive forces through technological innovation[38]. - The company has 335 R&D personnel, representing 47.8% of total employees[143]. - The company has developed a new intelligent production line for lithium battery materials, achieving automation and flexibility in production[145]. - The company is in the R&D phase for sodium battery anode materials, with key equipment design completed and prototype testing underway[145]. - The company has developed unique technologies to meet the higher production requirements for high-nickel NCM811 cathode materials, enhancing its competitive edge in the lithium battery sector[73]. Market Position and Strategy - The company aims to establish a new business model focusing on "core manufacturing (equipment, materials) + comprehensive services (technology, capital)" with a vision of becoming a world-class enterprise[46]. - The company is positioned as a global competitive manufacturer and service provider in the new energy materials and petrochemical sectors, with a focus on high-end, intelligent, and green manufacturing[127]. - The company is actively pursuing market expansion and technological innovation to enhance its service capabilities and maintain competitiveness in the industry[129]. - The company is committed to internationalization, with plans to expand its global market presence through overseas investments and mergers[167]. - The company is focusing on high-end manufacturing and aims to break through "bottleneck" technologies to enhance its competitiveness in the high-end market[164]. Industry Trends - In 2024, global new energy vehicle sales reached 18.236 million units, a year-on-year increase of 24.4%[60]. - The cumulative installed capacity of global power batteries in 2024 was 894.4 GWh, with a year-on-year increase of 27.2%[60]. - The total output value of the lithium battery industry in China exceeded 1.2 trillion yuan in 2024[63]. - The competition in the equipment manufacturing market is shifting from price competition to performance and technology competition, indicating a trend towards market differentiation[166]. - The renewable energy industry is becoming a key driver of economic growth globally, with significant advancements in wind, solar, biomass, geothermal, and hydrogen energy technologies[161]. Operational Developments - The company has 15 ongoing general contracting projects, all of which met their annual progress targets[39]. - The construction of the 100,000 tons/year lithium iron phosphate project for Guizhou Phosphate Kai Rui Technology has reached 60% completion in production line installation[40]. - The company is expanding its lithium battery business across the entire industry chain, from project initiation to intelligent operation management[48]. - The company is constructing a smart factory for 50,000 tons of lithium iron phosphate cathode materials, optimizing layout to reduce logistics time and improve production efficiency[89]. - The company has developed a complete set of technology for the treatment of benzopyrene in cold-cut coke water, achieving a discharge standard of less than 3×10^-5 mg/L[144]. Customer Relationships - The company has maintained long-term partnerships with key clients such as CATL and BASF, indicating robust customer relationships in the new energy sector[122]. - The company has established a stable customer base across multiple sectors, including new energy materials and petrochemicals, enhancing its market reputation[123]. Future Outlook - The government aims for new energy vehicles to account for about 20% of total new car sales by 2025[62]. - The renewable energy sector is expected to enter the TWh era in the coming years, driven by increasing energy demand and the need for structural optimization[168]. - The company aims to provide comprehensive solutions for smart factory construction in the new energy and new materials sectors, focusing on high-end intelligent equipment manufacturing and services[105].

Financial Performance - The company's operating revenue for Q1 2025 was ¥77,062,237.46, representing a 116.27% increase compared to ¥35,633,143.76 in the same period last year[4]. - Net profit attributable to shareholders decreased by 34.65% to ¥3,426,112.19 from ¥5,242,315.57 year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 30.93% to ¥3,293,843.93 compared to ¥4,768,546.05 in the previous year[4]. - The basic earnings per share decreased by 25.00% to ¥0.03 from ¥0.04 in the same period last year[6]. - Operating profit for Q1 2025 was ¥2,989,535.61, slightly down from ¥3,059,665.14 in Q1 2024, indicating a decrease of 2.3%[16]. - Net profit for Q1 2025 was ¥1,421,430.66, a decline of 39.7% from ¥2,357,351.02 in Q1 2024[16]. - Earnings per share for Q1 2025 were ¥0.03, compared to ¥0.04 in Q1 2024, reflecting a 25% decrease[17]. - The company reported a total operating cost of ¥70,665,174.04 for Q1 2025, up 105.6% from ¥34,358,791.33 in Q1 2024[15]. - The company recorded an investment loss of ¥3,135,299.41 in Q1 2025, slightly higher than the loss of ¥3,068,294.00 in Q1 2024[16]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥28,754,383.31 from -¥64,638,160.26 year-on-year, indicating a reduction in cash payments for goods[4][8]. - Cash flow from operating activities for Q1 2025 was negative at -¥28,754,383.31, an improvement from -¥64,638,160.26 in Q1 2024[21]. - The company reported a decrease in cash and cash equivalents to RMB 80,918,614.87 from RMB 123,838,936.62, a decline of about 34.6%[11]. - The beginning balance of cash and cash equivalents was $121,835,498.45, down from $233,701,032.61 year-over-year[22]. - The ending balance of cash and cash equivalents stood at $80,317,242.86, a decrease from $153,157,170.00 compared to the previous period[22]. - Total assets at the end of the reporting period were ¥1,473,615,747.45, a slight increase of 0.52% from ¥1,466,011,224.89 at the end of the previous year[6]. - The company's total assets as of March 31, 2025, amount to RMB 1,473,615,747.45, an increase from RMB 1,466,011,224.89 at the end of 2024[12]. - Current assets total RMB 735,762,983.90, slightly down from RMB 748,323,890.23[12]. - Accounts receivable increased to RMB 463,092,641.05 from RMB 411,897,556.09, reflecting a growth of approximately 12.4%[11]. - Inventory decreased to RMB 71,694,634.53 from RMB 99,691,956.05, a decline of about 28.1%[12]. - Total liabilities increased to RMB 311,614,976.77 from RMB 305,431,884.87, indicating a rise of approximately 2.1%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,423[10]. - The largest shareholder, Dai Jianwei, holds 57,113,219 shares, representing 42.00% of total shares[10]. - The number of shares held by the top 10 shareholders remains unchanged, indicating stability in shareholder structure[11]. - The company has no significant changes in its transfer and lending business, maintaining a stable operational environment[11]. Business Strategy and Market Conditions - The company is actively expanding into emerging businesses such as intelligent static distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[8]. - The company reported a significant impact from the global economic slowdown and reduced domestic market demand, affecting overall profitability[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[15]. - Research and development expenses for Q1 2025 were ¥4,821,605.40, down 27% from ¥6,600,012.24 in Q1 2024[15].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 607,540,524.76, representing an increase of 18.06% compared to CNY 514,607,850.91 in the same period last year[4] - Net profit attributable to shareholders was CNY 8,734,328.12, a significant turnaround from a loss of CNY 85,199,301.16 in the previous year, marking an increase of 110.25%[4] - The basic earnings per share (EPS) improved to CNY 0.01 from a loss of CNY 0.14, reflecting a 107.14% increase[4] - The weighted average return on equity rose to 0.33%, an increase of 3.43 percentage points from -3.10% in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 4,238,340.27, a 104.84% increase from a loss of CNY 87,580,174.89 in the previous year[4] - The company reported a significant increase in sales volume and price for glass fiber yarn, which positively impacted revenue and net profit[7] - Total operating revenue for Q1 2025 reached ¥607,540,524.76, an increase of 18.1% compared to ¥514,607,850.91 in Q1 2024[18] - Net profit for Q1 2025 was ¥8,734,328.12, a significant recovery from a net loss of ¥85,199,301.16 in Q1 2024[19] - Operating profit improved to ¥12,569,948.69 from a loss of ¥81,562,781.73 year-over-year[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,484,873,269.52, up 4.86% from CNY 7,138,031,412.86 at the end of the previous year[5] - Total assets reached ¥7,484,873,269.52, up from ¥7,138,031,412.86, reflecting an increase of approximately 4.9%[12] - Total liabilities increased to ¥4,845,156,527.16 from ¥4,510,071,100.22, marking a rise of about 7.4%[14] - The total liabilities increased to CNY 1,876,260,371.97 as of March 31, 2025, compared to CNY 1,567,316,460.09 at the end of 2024[28] - The company's total current liabilities are ¥2,444,017,533.52, slightly up from ¥2,443,609,907.47[14] - Long-term borrowings rose to ¥1,751,030,269.93 from ¥1,438,566,113.77, indicating an increase of approximately 21.7%[14] Cash Flow - The net cash flow from operating activities was negative at CNY -48,130,163.74, a decrease of 152.75% compared to CNY 91,248,428.34 in the same period last year[4] - Cash flow from operating activities showed a net outflow of ¥48,130,163.74, compared to a net inflow of ¥91,248,428.34 in Q1 2024[23] - Total cash inflow from operating activities in Q1 2025 was ¥91,701,031.41, down from ¥100,737,352.83 in Q1 2024, representing a decrease of approximately 8.5%[34] - Cash outflow for purchasing goods and services in Q1 2025 was ¥37,526,077.51, a decrease of 37% from ¥59,585,592.50 in Q1 2024[34] - The cash flow from financing activities for Q1 2025 was CNY 109,406,202.57, compared to CNY 164,083,746.90 in Q1 2024, showing a decrease of about 33%[25] Shareholder Information - The total equity attributable to shareholders was CNY 2,639,716,742.36, a slight increase of 0.45% from CNY 2,627,960,312.64 at the end of the previous year[5] - The total number of ordinary shares at the end of the reporting period is 28,576[10] - The largest shareholder, Shandong Energy Group New Materials Co., Ltd., holds 316,441,633 shares, accounting for 51.79% of total shares[10] Research and Development - Research and development expenses decreased to ¥18,762,218.85 from ¥22,991,917.26, a decline of 18.8%[19] - Research and development expenses for Q1 2025 were CNY 6,559,574.55, down from CNY 11,885,118.20 in Q1 2024, indicating a reduction of approximately 44%[30] Government Support - The company received government subsidies amounting to CNY 4,401,550.76, which contributed to the non-recurring gains[6]

Company Performance - The company's operating revenue for 2024 was ¥66,341,007.26, a decrease of 31.31% compared to ¥96,578,667.69 in 2023[28]. - The net profit attributable to shareholders was -¥4,159,237.26, representing a decline of 135.74% from ¥11,638,296.15 in the previous year[28]. - The gross profit margin improved to 72.23% in 2024, up from 68.49% in 2023[28]. - Total assets decreased by 1.72% to ¥272,071,080.39 from ¥276,828,764.33 at the end of 2023[30]. - Total liabilities increased by 23.19% to ¥30,661,896.67 compared to ¥24,889,399.35 at the end of 2023[30]. - The net asset attributable to shareholders decreased by 4.18% to ¥241,409,183.72 from ¥251,939,364.98 in 2023[30]. - The operating cash flow for 2024 was ¥28,859,827.45, down 9.95% from ¥32,050,406.98 in 2023[30]. - The company reported a basic earnings per share of -¥0.04, a decrease of 136.36% from ¥0.11 in 2023[28]. - The revenue for the fourth quarter (October-December) was ¥37,885,326.57, contributing significantly to the annual total[35]. Research and Development - The company holds 17 invention patents and 72 copyrights, with over 20% of revenue invested in R&D in recent years[53]. - The company's R&D expenses increased by 2.30% to 23.47 million yuan, representing 35.38% of total revenue in 2024[82]. - The total number of R&D personnel increased to 125, with the proportion of R&D staff to total employees rising to 51.65%[110]. - The company is currently developing a high-definition digital human project aimed at enhancing clinical medical product development and increasing market share[112]. - A virtual reality training project for clinical anesthesia is in development, addressing the significant talent gap in anesthesiology in China[113]. - The company is working on a cell-level 3D reconstruction system that aims to visualize microanatomical structures, significantly changing disease structure research methods[116]. - The digital human anatomy system is being upgraded based on the latest digital human data to enhance its functionality and competitiveness in the digital anatomy field[117]. - The company is collaborating with universities to obtain high-definition human imaging data for its projects, enhancing its research capabilities[112]. Market Presence and Strategy - The company has established a market presence in over 500 medical institutions nationwide and has initiated pilot sales in over 40 countries[46]. - The company plans to expand its business from medical education to clinical medicine and public health[53]. - The company aims to enhance its core competitiveness and expand market applications through a dual-driven development model of "data accumulation" and "technological innovation"[147]. - By 2025, the company plans to maintain a leading market share with a focus on "application-oriented" strategies, including the promotion of virtual anatomy laboratories and the integration of AI in curriculum development[148]. - The company is committed to corporate social responsibility by providing quality products and services, ensuring employee rights, and contributing to humanitarian efforts[130]. Financial Management and Audit - The company has appointed Xinyong Zhonghe Accounting Firm as its auditor, which issued a qualified audit opinion for the financial report[14]. - The audit report issued by the accounting firm includes a qualified opinion due to the inability to obtain sufficient audit evidence regarding the recognition of accounts receivable[122]. - The company will implement measures to strengthen internal controls and compliance checks to mitigate operational risks and protect shareholder interests[124]. - The company has received a high-tech enterprise certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for the year 2024[105]. - The company plans to enhance accounts receivable management by refining customer credit assessment and collection processes to ensure timely and secure cash flow[124]. Innovation and Technology Integration - The company is focused on integrating technology and service to enhance brand recognition and market competitiveness[64]. - The company aims to leverage advanced technologies like virtual reality and artificial intelligence to enhance digital education resources[59]. - The company is committed to integrating AI and multi-modal technologies into product development to enhance educational outcomes[45]. - The company is leveraging innovative technologies such as VR/AR to enhance its educational offerings and expand its market presence[114]. Challenges and Risks - The company faces risks from potential changes in national policies that could impact the medical informationization industry, which it plans to mitigate by closely tracking policy developments[151]. - Increased market competition is anticipated, prompting the company to enhance R&D investments and maintain product leadership through innovation and collaboration[152]. - The company recognizes the risk of not accurately grasping industry trends and plans to strengthen product development and sales efforts to counteract potential negative impacts[152]. - The company has identified significant uncertainty regarding the recoverability of accounts receivable over one year old, leading to the estimation of bad debt provisions[123]. Corporate Governance and Management - The company is committed to improving its financial management system, enhancing accounting information quality, and establishing effective internal control and risk prevention mechanisms[67]. - The board of directors is committed to enhancing corporate governance and internal control processes to eliminate risks and promote healthy development[162]. - The company continues to focus on expanding its management team with experienced professionals from diverse backgrounds[199]. - The company is actively managing its leadership transitions to ensure continuity and stability in its operations[198].

Financial Performance - The company's operating revenue for Q1 2025 was ¥116,970,726.28, a decrease of 31.85% compared to ¥171,646,888.71 in the same period last year[4] - Net profit attributable to shareholders increased by 46.02% to ¥6,612,981.16 from ¥4,528,825.64 year-on-year[4] - Basic and diluted earnings per share rose by 50.00% to ¥0.06 from ¥0.04 in the previous year[4] - The company reported a net profit excluding non-recurring gains and losses of ¥6,600,809.39, up 46.59% from ¥4,502,822.77 in the same period last year[4] - The net profit for Q1 2025 is CNY 6,506,920.68, a decrease of 47.3% compared to CNY 12,322,374.46 in Q1 2024[18] - The operating profit for Q1 2025 is CNY 6,627,751.67, down from CNY 12,310,753.30 in the same period last year, reflecting a decline of 46.1%[18] - The total comprehensive income for Q1 2025 is CNY 6,506,920.68, a decrease of 47.3% from CNY 12,322,374.46 in Q1 2024[19] - The company reported a decrease in sales revenue from CNY 119,405,572.22 in Q1 2024 to CNY 97,922,158.77 in Q1 2025, a decline of 18.0%[22] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥1,402,279.08, a 97.52% increase compared to -¥56,584,590.85 in the same period last year[4] - Cash flow from operating activities for Q1 2025 is negative at CNY -1,402,279.08, compared to CNY -56,584,590.85 in Q1 2024[23] - The cash outflow from operating activities in Q1 2025 is CNY 107,280,495.11, compared to CNY 225,069,312.21 in Q1 2024, indicating a reduction of 52.3%[23] - Total cash and cash equivalents at the end of Q1 2025 is CNY 66,884,961.85, down from CNY 108,040,718.30 at the end of Q1 2024[24] - The beginning balance of cash and cash equivalents was 78,666,790.82, down from 119,583,155.87[31] - The ending balance of cash and cash equivalents was 62,896,066.34, compared to 69,912,094.69 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,186,594,148.13, reflecting a slight increase of 0.72% from ¥1,178,054,042.99 at the end of the previous year[5] - Total liabilities as of March 31, 2025, were CNY 1,099,576,418.29, slightly up from CNY 1,097,543,233.83 as of December 31, 2024[15] - The total assets increased to ¥1,446,557,443.58 in the latest reporting period, up from ¥1,387,823,360.76[26] - The total liabilities rose to ¥916,582,270.13, compared to ¥859,727,831.11 in the previous period, indicating a 6.7% increase[26] Equity and Shareholder Information - Shareholders' equity attributable to shareholders increased by 3.64% to ¥188,231,049.96 from ¥181,618,068.80 at the end of the previous year[5] - The company's equity attributable to shareholders as of March 31, 2025, was CNY 188,231,049.96, an increase from CNY 181,618,068.80 as of December 31, 2024[16] - The company's total equity increased slightly to ¥529,975,173.45 from ¥528,095,529.65[26] Cost Management - The decrease in operating revenue was attributed to a reduction in project acceptance[9] - The company plans to continue focusing on cost reduction strategies to enhance profitability in the upcoming quarters[9] - Total operating costs for Q1 2025 were CNY 110,860,055.63, down 30% from CNY 158,070,558.74 in Q1 2024[17] - Research and development expenses in Q1 2025 amounted to CNY 6,927,780.45, a decrease of 42.5% compared to CNY 12,149,124.66 in Q1 2024[17] - Research and development expenses for Q1 2025 were ¥6,051,974.72, a decrease from ¥7,342,102.18 in Q1 2024[27] Borrowings - Short-term borrowings as of March 31, 2025, were CNY 123,763,538.14, a decrease of 16.3% from CNY 147,801,167.84 as of December 31, 2024[15] - The company’s short-term borrowings decreased to ¥93,224,947.73 from ¥116,662,577.43, indicating a reduction in short-term debt[26]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 5,435,220,089, a decrease of 1.88% compared to CNY 5,539,130,441 in the same period last year[4]. - Net profit attributable to shareholders decreased by 21.98% to CNY 250,636,310 from CNY 321,257,612 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 243,498,304, down 21.59% from CNY 310,558,626 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.33, a decrease of 21.43% from CNY 0.42 in the previous year[6]. - The weighted average return on equity decreased by 0.94 percentage points to 3.74% from 4.68% year-on-year[6]. - Total operating revenue for Q1 2025 was CNY 5,435,220,089, a decrease of 1.88% compared to CNY 5,539,130,441 in Q1 2024[46]. - Net profit for Q1 2025 was CNY 287,724,682, a decrease of 21.43% from CNY 366,283,797 in Q1 2024[48]. - Earnings per share for Q1 2025 was CNY 0.33, down from CNY 0.42 in Q1 2024[48]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 92.84% to CNY 804,266,875, compared to CNY 417,071,839 in the same period last year[4][8]. - Cash flow from operating activities for Q1 2025 showed a positive trend, indicating improved liquidity[50]. - Cash flow from operating activities for Q1 2025 was $804,266,875, a significant increase of 92.7% compared to $417,071,839 in Q1 2024[52]. - Total cash inflow from operating activities decreased to $6,128,888,296 in Q1 2025 from $6,350,017,708 in Q1 2024, reflecting a decline of 3.5%[52]. - Cash outflow from operating activities decreased to $5,324,621,421 in Q1 2025 from $5,932,945,869 in Q1 2024, a reduction of 10.2%[52]. - The ending cash and cash equivalents balance for Q1 2025 was $937,559,666, down from $992,416,096 in Q1 2024[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 21,032,492,621, a slight decrease of 0.06% from CNY 21,044,853,679 at the end of the previous year[6]. - Total liabilities decreased to CNY 13,617,227,310 from CNY 13,888,903,390[42]. - The equity attributable to shareholders increased to CNY 6,831,826,301 from CNY 6,580,857,270[42]. Store and Market Expansion - As of Q1 2025, the company has a total of 15,252 stores, including 9,844 direct-operated and 5,408 franchised stores, with a net addition of 211 stores during the quarter[13]. - The company has expanded its market presence to cover 18 provincial markets and over 150 cities, focusing on 11 key provinces to enhance market share[13]. - The total number of ordinary shareholders at the end of the reporting period was 48,022[10]. Sales and Revenue Streams - The company achieved a gross margin of 34.22% in Q1 2025, with offline store sales gross margin increasing by 0.70 percentage points year-on-year[19]. - The company’s membership total reached 102.05 million, with 15.46 million active members in Q1 2025, and membership sales accounted for 73% of total sales[24]. - The company’s supply chain resources supported franchise development, resulting in a delivery revenue of over 580 million RMB in Q1 2025[14]. - The company’s alliance business achieved a delivery sales amount of 126 million RMB in Q1 2025, representing a year-on-year growth of 34%[16]. - The company’s self-owned brand sales exceeded 900 million RMB in Q1 2025, with a sales proportion of approximately 23.3%, an increase of 2.5 percentage points year-on-year[20]. - The company’s online sales (including franchises) reached approximately CNY 750 million, a year-on-year increase of 34%[26]. - Private domain sales increased by 58.5% year-on-year during the Spring Festival period, with new product sales accounting for over 18% of private domain sales[26]. Research and Development - Research and development expenses increased significantly to CNY 8,405,207 in Q1 2025 from CNY 196,068 in Q1 2024[46]. Other Notable Information - The company received government subsidies amounting to CNY 8,051,561, which are closely related to its normal operations[7]. - The company acquired a 20% stake in Hunan Laobaixing Huairen Pharmacy Chain Co., Ltd. for CNY 385 million, with the transaction yet to be completed[37][38]. - The company successfully opened 3 diversified stores, with non-pharmaceutical sales accounting for an increase of 2.8 percentage points[27]. - The company’s SKU count reached approximately 25,100, with inventory turnover days reduced to 92 days, a decrease of 13 days year-on-year[20]. - The company has 9,158 stores with various medical insurance qualifications, representing 93.03% of its direct-operated stores[35]. - The gross profit margin for the retail segment decreased by 0.52 percentage points to 38.40%, primarily due to the increased proportion of online business[29]. - The daily active users (DAU) of the mini-program mall increased by 70% year-on-year, surpassing 200,000[26].

Financial Performance - The company's operating revenue for Q1 2025 was ¥127,454,602.98, a decrease of 28.88% compared to the same period last year[4] - Net profit attributable to shareholders was ¥3,568,395.59, representing a significant increase of 121.24% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,252,870.94, up 106.62% from the previous year[4] - Basic and diluted earnings per share were both ¥0.02, reflecting a 122.22% increase compared to -¥0.09 in the previous year[4] - The net profit for the first quarter of 2025 was CNY 3,568,395.59, compared to a net loss of CNY 16,861,026.10 in the same period of 2024, indicating a significant recovery[19] - The total comprehensive income for the first quarter of 2025 was CNY 4,039,991.36, compared to a total comprehensive loss of CNY 16,861,026.10 in the first quarter of 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities improved to -¥10,711,910.87, an 83.52% reduction in cash outflow compared to the same period last year[4] - Operating cash flow for the first quarter of 2025 was negative CNY 10,711,910.87, an improvement from negative CNY 64,982,668.10 in the first quarter of 2024[21] - Cash inflow from operating activities totaled CNY 130,013,055.60 in the first quarter of 2025, down from CNY 226,049,900.53 in the first quarter of 2024[20] - Cash outflow from operating activities was CNY 140,724,966.47 in the first quarter of 2025, compared to CNY 291,032,568.63 in the first quarter of 2024[21] - The cash and cash equivalents at the end of the first quarter of 2025 were CNY 614,765,074.72, down from CNY 636,514,145.34 at the end of the first quarter of 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,422,375,458.34, a decrease of 2.92% from the end of the previous year[5] - Total assets as of March 31, 2025, were CNY 1,422,375,458.34, down from CNY 1,465,151,807.70 at the end of 2024[15] - Total liabilities decreased to CNY 398,755,574.58 from CNY 445,836,095.19, a reduction of approximately 10%[14] - Shareholders' equity attributable to shareholders increased slightly to ¥1,023,619,883.76, up 0.42% from the previous year[5] Operating Performance - Total revenue for Q1 2025 was CNY 127,454,602.98, a decrease of 29% compared to CNY 179,202,955.04 in Q1 2024[16] - Total operating costs for Q1 2025 were CNY 125,296,484.88, down 36% from CNY 195,934,002.74 in Q1 2024[16] - Operating income for Q1 2025 was CNY 2,158,118.10, compared to a loss in Q1 2024[16] - The company reported a net profit margin improvement due to reduced operating costs despite lower revenue[16] Research and Development - Research and development expenses for Q1 2025 were CNY 5,404,701.70, down from CNY 8,745,285.10 in Q1 2024, reflecting a decrease of about 38%[16] Non-Recurring Items - Non-recurring gains and losses totaled ¥2,315,524.65, primarily from government subsidies and other income[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,940[9] Investment Activities - The company reported investment cash inflow of CNY 572,316,072.80 in the first quarter of 2025, compared to CNY 360,087,999.69 in the first quarter of 2024[21] - The net cash flow from investment activities was CNY 1,505,675.62 in the first quarter of 2025, compared to CNY 169,642,685.72 in the first quarter of 2024[21] Mergers and Acquisitions - The company did not execute any mergers or acquisitions during the reporting period[22]

Dividend Distribution - The proposed cash dividend distribution is 0.8 CNY per 10 shares, totaling 60,807,649.04 CNY (including tax) for the year 2024, which accounts for 60.15% of the net profit attributable to shareholders [6]. - The total cash dividend for 2024, including the mid-year dividend of 251,408,449.24 CNY, amounts to 312,216,098.28 CNY (including tax) [6]. - The company implemented a mid-term dividend of 251 million yuan in 2024, with a commitment to maintain a minimum of 50% of net profit as cash dividends from 2024 to 2026 [91]. - The cumulative cash dividend over the last three accounting years was CNY 990,583,068 [191]. - The average net profit over the last three accounting years was CNY 744,349,352, resulting in a cash dividend ratio of 133.08% [191]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2024, representing a year-over-year growth of 15% [16]. - The company's operating revenue for 2024 was CNY 22,357,610,195, a slight decrease of 0.36% compared to 2023 [24]. - Net profit attributable to shareholders decreased by 44.13% to CNY 519,063,405, primarily due to the increase in the number of new stores and goodwill impairment losses [26]. - The net cash flow from operating activities fell by 25.77% to CNY 2,026,458,797, attributed to reduced cash receipts from sales and increased payroll expenses from new store openings [26]. - Basic earnings per share dropped by 44.72% to CNY 0.68, reflecting the overall decline in profitability [25]. - The weighted average return on equity decreased to 7.84%, down from 13.91% in the previous year, indicating a significant reduction in efficiency [25]. Market Expansion and Strategy - The company plans to expand its market presence by opening 50 new stores across various provinces in 2024 [16]. - A strategic acquisition of a regional pharmacy chain is anticipated to enhance distribution capabilities and increase market share by 10% [16]. - The company aims to enhance its online-to-offline (O2O) model, targeting a 30% increase in online sales by the end of 2024 [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [160]. - The company is exploring potential mergers and acquisitions to enhance growth opportunities [158]. Risk Management - The company has reported no significant risks that could materially affect its operations during the reporting period [8]. - The company has detailed various risks and countermeasures in the management discussion and analysis section of the report [8]. - The company emphasizes the importance of investor awareness regarding investment risks related to forward-looking statements [7]. - The company faces industry policy risks due to increasing regulatory scrutiny in the pharmaceutical retail sector, which could adversely affect its development if not managed properly [144]. - To mitigate market competition risks, the company will continue its digital transformation and improve operational efficiency through AI and big data technologies [144]. Operational Efficiency - The gross margin for the last quarter was reported at 35%, a slight improvement from 33% in the previous year [16]. - The company has allocated RMB 100 million for research and development in new drug formulations and delivery systems [16]. - The company reduced inventory turnover days to 94 days by the end of 2024, a decrease of 4 days year-on-year, while the proportion of centralized procurement sales increased to 72.4% [86]. - The company completed 479 non-operational procurement projects in 2024, achieving a cost reduction of over 16 million yuan, with a reduction rate of over 7% [86]. - The company is enhancing its quality and compliance management systems, establishing a four-level quality management structure [98]. Customer Engagement and Satisfaction - User data indicates an increase in active customers by 20% to 3 million in the last quarter [16]. - The company’s total membership reached 99.65 million by the end of 2024, with 30.34 million active members and a membership sales contribution exceeding 75% [90]. - Customer satisfaction ratings have improved, with a reported 90% satisfaction rate in recent surveys [160]. - The company has established a smart chronic disease management service system, with over 18.12 million people registered for chronic disease management services and 99.23 million self-testing services provided by the end of 2024 [82]. Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining transparency in decision-making processes [149]. - The company disclosed a total of 89 announcements during the reporting period, adhering to legal obligations for accurate and timely information disclosure [150]. - The company has undergone a board election, resulting in the appointment of new directors including Xie Jiaqi and Liu Xiaoen [165]. - The company is committed to aligning its compensation practices with shareholder interests through board approval processes [164]. - The company continues to focus on governance and compliance through regular board elections and management reviews [165]. Research and Development - The company has invested 1.23 million RMB in environmental protection during the reporting period [199]. - Research and development expenses totaled 136,011,931, representing 0.61% of total revenue, with 98.52% of R&D costs capitalized [115]. - Investment in R&D has increased by 30%, focusing on innovative technologies and product development [161]. - The number of R&D personnel is 434, making up 1.08% of the total workforce [116]. - The company has developed 1,900 courses on its learning platform, with a total of over 769 million learning instances [179].